Latest news with #Reveal
The Star
2 days ago
- Entertainment
- The Star
K-pop singer Ju Hak-nyeon denies paying for sex
South Korean singer Ju Hak-nyeon was reported to have had a personal meeting with a Japanese adult film actress-turned-influencer. Photo: Ju Hak-nyeon/Instagram South Korean singer Ju Hak-nyeon has admitted in a letter of apology to meeting a former Japanese adult actress, but denied rumours of being involved in prostitution activities. The apology on June 19 came after he was booted from K-pop boy band The Boyz on June 18. His agency One Hundred Label had announced on June 16 that the 26-year-old would be taking a break for personal reasons, without providing details. A Japanese media outlet then reported that Ju had a personal meeting with a Japanese adult film actress-turned-influencer, who is 11 years his senior, in Tokyo. The outlet added that he had allegedly paid for sex with the woman. One Hundred Label announced on June 18 that Ju will leave The Boyz and that his exclusive contract with the agency has been terminated. On June 19, Ju uploaded a handwritten letter on social media, in which he apologised for his behaviour. He admitted that he had a drink with an actress, along with acquaintances, in May. But he said he did not pay for sex, insisting that he had not committed any illegal acts. The Boyz, originally a 12-man act, debuted in 2017 with the EP The First. One member, Hwall, departed in October 2019 and the band released their first studio album, Reveal, in 2020. They launched their third studio album, Unexpected , in March. It was the band's first release since signing with One Hundred Label in late 2024 after leaving management company IST Entertainment. – The Korea Herald/Asia News Network
Straits Times
3 days ago
- Entertainment
- Straits Times
Ju Hak-nyeon, formerly of K-pop boy band Boyz, denies paying for sex
South Korean singer Ju Hak-nyeon was reported to have had a 'personal' meeting with a Japanese adult film actress turned influencer. PHOTO: JUHAKNYEON/INSTAGRAM SEOUL – South Korean singer Ju Hak-nyeon has admitted in a letter of apology to meeting a former Japanese adult actress, but denied rumours of being involved in prostitution activities. The apology on June 19 came after he was booted from K-pop boy band The Boyz on June 18. His agency One Hundred Label had announced on June 16 that the 26-year-old would be taking a break for personal reasons, without providing details. A Japanese media outlet then reported that Ju had a 'personal' meeting with a Japanese adult film actress turned influencer, who is 11 years his senior, in Tokyo. The outlet added that he had paid for sex with the woman. One Hundred Label announced on June 18 that Ju would leave the band and that his exclusive contract with the agency has been terminated. On June 19, Ju uploaded a handwritten letter on social media, in which he apologised for his behaviour. He admitted that he had a drink with an actress, along with acquaintances, in May. But he said he did not pay for sex, insisting that he had not committed any illegal acts. The Boyz, originally a 12-member act, debuted in 2017 with the EP The First. Hwall departed in October 2019 and the band released their first studio album, Reveal, in 2020. They launched their third studio album, Unexpected, in March. It was the band's first release since signing with One Hundred in late 2024 after leaving management company IST Entertainment. THE KOREA HERALD/ASIA NEWS NETWORK Join ST's Telegram channel and get the latest breaking news delivered to you.
Business Wire
12-06-2025
- Business
- Business Wire
Wendell Jisa, Founder & CEO of Reveal, Wins EY Entrepreneur Of The Year® 2025 Award
CHICAGO--(BUSINESS WIRE)-- Reveal, the global provider of dual eDiscovery and investigation platforms powered by a single, unified AI engine, proudly announces that its Founder and CEO, Wendell Jisa, has been named a 2025 EY Entrepreneur Of The Year® Midwest Award winner—one of the most prestigious recognitions in business leadership and innovation. The award celebrates Jisa's extraordinary journey from startup founder to industry disruptor. His vision: to modernize the legal industry by making artificial intelligence not just accessible, but essential to how legal professionals work. By infusing advanced AI into every stage of the eDiscovery process, Jisa and the entire team at Reveal are empowering legal teams to surface key insights faster, cut through data noise with precision, and unlock greater value from their work. The culture of innovation Jisa continues to cultivate at Reveal raises the bar for what's possible in legal tech. 'From day one, we set out to reimagine what legal professionals could do if they had the right tools,' Jisa said. 'We didn't want to replace people—we wanted to amplify them. This award is a powerful recognition of that mission. I'm deeply honored, and grateful to the exceptional Reveal team and our forward-thinking clients who believed in this from the very beginning.' Under Wendell Jisa's leadership, Reveal has grown into a multi-platform global enterprise—driven by his visionary Build, Buy, Partner strategy. Through strategic acquisitions—including Brainspace, Logikcull, Onna and others—Reveal has rapidly expanded its capabilities, creating the most comprehensive legal intelligence ecosystem in the industry. Simultaneously, Jisa has fostered a culture of internal innovation, resulting in breakthrough tools like 'ASK,' a generative AI-powered search feature, and GenAI Review, which streamlines document analysis and accelerates review across both Reveal Enterprise and Logikcull by Reveal. In parallel, he has forged and nurtured strategic partnerships across cloud, data, and integration ecosystems—ensuring Reveal clients benefit from the most flexible, powerful, and forward-looking AI-powered eDiscovery offerings on the market today. 'The Entrepreneur Of The Year 2025 Midwest Award winners are trailblazers who redefine excellence and set new benchmarks in their industries,' said Ram Ramanan, Entrepreneur Of The Year Midwest Program Director. 'They set the standard for scaling businesses while prioritizing their employees, customers and communities.' Jisa's win makes him eligible for the EY Entrepreneur Of The Year® 2025 National Awards, to be announced this fall at the Strategic Growth Forum® in Palm Springs, California. For more information about Reveal and its AI-powered eDiscovery solutions, visit About Reveal Reveal is a leading AI-powered platform for eDiscovery, document review, legal hold and investigations. The company has a deep history in driving the adoption of legal automation, which is underpinned by its leading processing technology, visual analytics, and artificial intelligence capabilities. Reveal's software combines technology and human guidance to transform structured and unstructured data into actionable insight. We help organizations, including law firms, corporations, government agencies, and intelligence services, uncover more useful information faster by providing a world-class user experience and AI technology that is embedded within every phase of the eDiscovery process. About EY Entrepreneur Of The Year® Founded in 1986, Entrepreneur Of The Year has celebrated more than 11,000 ambitious visionaries who are leading successful, dynamic businesses in the US, and it has since expanded to nearly 60 countries globally. The US program consists of 17 regional programs whose panels of independent judges select the regional award winners every June. Those winners compete for national recognition at the Strategic Growth Forum ® in November where National finalists and award winners are announced. The overall National winner represents the US at the EY World Entrepreneur Of The Year™ competition. Visit
Yahoo
09-06-2025
- Business
- Yahoo
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
LIBERATE Study: Guardant Reveal showed high sensitivity and 100% positive predictive value for relapse PALO ALTO, Calif., June 09, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company's minimal residual disease (MRD) blood test, in predicting recurrence in patients with early-stage breast cancer. Guardant Reveal uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA) in a patient's blood without the need for a tissue sample. The LIBERATE study retrospectively analyzed 290 blood samples from 95 patients who were diagnosed with early-stage ER+/HER2- or triple negative breast cancer undergoing chemotherapy prior to surgery, half of whom had localized disease with no lymph node involvement. Nearly 40% had minimal or no residual tumor by pathologic assessment following neoadjuvant chemotherapy. Key findings include: High Sensitivity and Specificity: Guardant Reveal demonstrated 100% sensitivity for distant recurrence in patients with ER+/HER2- breast cancer (which represents about 70% of all breast cancers), and 71% overall, with 100% specificity and 100% positive predictive value for relapse. Significant Prognostic Power: Detection of ctDNA post-operatively was significantly prognostic for event-free survival (EFS), with median lead time of 152 days (range: 15-748 days) ahead of clinical recurrence (P < 0.0001). Nearly 100% of All Samples Evaluable: All patients with post-operative blood samples had MRD results available from Reveal, highlighting the power of a tissue-free MRD test among patients receiving neoadjuvant therapy, particularly the large percentage who have minimal to no tumor found at surgery. "This study underscores the clinical validity, robust prognostic value and high specificity of Guardant Reveal in identifying breast cancer patients at elevated risk of recurrence without the need for a tissue sample," said Craig Eagle, M.D., Guardant Health chief medical officer. "These findings reinforce the critical role Reveal can achieve in clinical decision-making, potentially transforming neoadjuvant and post-treatment surveillance strategies and improving patient outcomes." This publication adds to the growing body of evidence of Reveal's strong performance in early-stage breast cancer. Earlier this year, a peer-reviewed publication in Clinical Cancer Research focused on stage II and III triple negative breast cancer demonstrated 83% sensitivity for metastatic recurrence and 99.5% sample-level specificity. Post-surgical ctDNA detection was prognostic for shorter recurrence-free interval (P < 0.0001). Additionally, ctDNA detection at the post-neoadjuvant, presurgical time point was associated with a shorter recurrence-free interval in patients with residual disease at surgery (P < 0.0001). The full manuscript in ESMO Open is available here. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Michael Weistpress@ +1 317-371-0035
Business Wire
09-06-2025
- Business
- Business Wire
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company's minimal residual disease (MRD) blood test, in predicting recurrence in patients with early-stage breast cancer. Guardant Reveal uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA) in a patient's blood without the need for a tissue sample. The LIBERATE study retrospectively analyzed 290 blood samples from 95 patients who were diagnosed with early-stage ER+/HER2- or triple negative breast cancer undergoing chemotherapy prior to surgery, half of whom had localized disease with no lymph node involvement. Nearly 40% had minimal or no residual tumor by pathologic assessment following neoadjuvant chemotherapy. Key findings include: High Sensitivity and Specificity: Guardant Reveal demonstrated 100% sensitivity for distant recurrence in patients with ER+/HER2- breast cancer (which represents about 70% of all breast cancers), and 71% overall, with 100% specificity and 100% positive predictive value for relapse. Significant Prognostic Power: Detection of ctDNA post-operatively was significantly prognostic for event-free survival (EFS), with median lead time of 152 days (range: 15-748 days) ahead of clinical recurrence (P < 0.0001). Nearly 100% of All Samples Evaluable: All patients with post-operative blood samples had MRD results available from Reveal, highlighting the power of a tissue-free MRD test among patients receiving neoadjuvant therapy, particularly the large percentage who have minimal to no tumor found at surgery. "This study underscores the clinical validity, robust prognostic value and high specificity of Guardant Reveal in identifying breast cancer patients at elevated risk of recurrence without the need for a tissue sample," said Craig Eagle, M.D., Guardant Health chief medical officer. "These findings reinforce the critical role Reveal can achieve in clinical decision-making, potentially transforming neoadjuvant and post-treatment surveillance strategies and improving patient outcomes." This publication adds to the growing body of evidence of Reveal's strong performance in early-stage breast cancer. Earlier this year, a peer-reviewed publication in Clinical Cancer Research focused on stage II and III triple negative breast cancer demonstrated 83% sensitivity for metastatic recurrence and 99.5% sample-level specificity. Post-surgical ctDNA detection was prognostic for shorter recurrence-free interval (P < 0.0001). Additionally, ctDNA detection at the post-neoadjuvant, presurgical time point was associated with a shorter recurrence-free interval in patients with residual disease at surgery (P < 0.0001). The full manuscript in ESMO Open is available here. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
